Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ101 for debridement of deep second-degree burns
NCT07025408Phase 2Recruiting
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KJ-101 in deep second-degree burn, sponsored by Shanghai Bao Pharmaceuticals Co., Ltd.. Started Jun 2025; status: recruiting.
02
Drugs
KJ-101
03
Conditions
deep second-degree burn
Beyond the preview
Go deeper on NCT07025408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025408.